Skip to content

The BRAvAdO Registry

BRAzilian Registry of Acute Coronary Syndrome in Oncologic Patients - The BRAvAdO Registry

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04222608
Acronym
BRAvAdO
Enrollment
600
Registered
2020-01-10
Start date
2016-09-01
Completion date
2021-09-01
Last updated
2020-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ACS - Acute Coronary Syndrome, Oncology

Keywords

Cardio-Oncology, Interventional Cardiology, Cancer, Oncology, Acute Coronary Syndrome, Myocardial Infarction

Brief summary

The BRAVADO Registry pretends to identify stratification, diagnosis, total atherosclerotic burden and treatment approaches in oncologic patients with Acute Coronary Syndrome (ACS) and identify strategies to improve health care quality

Interventions

None listed

Sponsors

Instituto do Cancer do Estado de São Paulo
CollaboratorOTHER
Beneficência Portuguesa de São Paulo
CollaboratorOTHER
Instituto de Cardiologia do Rio Grande do Sul
CollaboratorOTHER
InCor Heart Institute
CollaboratorOTHER
University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Definitive cancer diagnosis - biopsy * Acute Coronary Syndrome - requiring urgent invasive risk stratification

Exclusion criteria

* KPS \< 60 , ECOG \>/ 3 * Life expectancy less 24hs * End of Life Care * Lack of consistent record data

Design outcomes

Primary

MeasureTime frameDescription
Major adverse cardiovascular events30 daysComposite endpoint of All-cause Death, Myocardial Infarction, Stroke and Myocardial Revascularization
Total Atherosclerotic burden and lesion complexity on angiography30 daysThe number and location of coronary lesions with obstructions greater than 50% were recorded. Each lesion was classified based on Ambrose's, Goldstein complexity, Leaman and SYNTAX scores.
Incidence of Major Bleeding30 daysRequiring a transfusion of ≥2 U PRBCs Resulting in a decrease in hematocrit of ≥10% Occurring intracerebrally Resulting in stroke or death

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026